Enoxacin-d8 (hydrochloride) |
Catalog No.GC48664
One-Click Copy Product Info
|
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2930288-95-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Enoxacin-d8 is intended for use as an internal standard for the quantification of enoxacin by GC- or LC-MS. Enoxacin is a fluoroquinolone antibiotic.1,2,3,4 It is active against clinical isolates of a variety of Gram-positive and Gram-negative bacteria, including S. aureus, E. coli, K. pneumoniae, P. aeruginosa, and S. marcescens (MIC50s = 1, 0.12, 0.25, 0.5, and 1 mg/L, respectively).1 Enoxacin inhibits S. aureus DNA gyrase supercoiling activity and topoisomerase IV DNA decatenation (IC50s = 126 and 26.5 µg/ml, respectively).2 It increases survival in mouse models of systemic S. aureus, E. coli, K. pneumoniae, P. aeruginosa, and S. marcescens infection with ED50 values of 15.1, 2.2, 4.1, 120.3, and 7.6 mg/kg, respectively.3 Enoxacin (4 and 8 mg/kg per day) also reduces tumor growth in a 143B human osteosarcoma mouse xenograft model.4 Formulations containing enoxacin have previously been used in the treatment of urinary tract infections and gonorrhea.
1.Clarke, A.M., Zemcov, S.J., and Campbell, M.E.In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new β-lactamsJ. Antimicrob. Chemother.15(1)39-44(1985) 2.Takei, M., Fukuda, H., Kishii, R., et al.Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibitionAntimicrob. Agents Chemother.45(12)3544-3547(2001) 3.Ozaki, M., Matsuda, M., Tomii, Y., et al.In vivo evaluation of NM441, a new thiazeto-quinoline derivativeAntimicrob. Agents Chemother.35(12)2496-2499(1991) 4.Luo, X., Liu, X., Tao, Q., et al.Enoxacin inhibits proliferation and invasion of human osteosarcoma cells and reduces bone tumour volume in a murine xenograft modelOncol. Lett.20(2)1400-1408(2020)
| Cas No. | 2930288-95-0 | SDF | |
| Canonical SMILES | CCN1C2=NC(N3C([2H])([2H])C([2H])([2H])NC([2H])([2H])C3([2H])[2H])=C(F)C=C2C(C(C(O)=O)=C1)=O.Cl | ||
| Formula | C15H9D8FN4O3•HCl | M.Wt | 364.8 |
| Solubility | DMSO: warmed,Water: soluble | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7412 mL | 13.7061 mL | 27.4123 mL |
| 5 mM | 548.2 μL | 2.7412 mL | 5.4825 mL |
| 10 mM | 274.1 μL | 1.3706 mL | 2.7412 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 18 reference(s) in Google Scholar.)